enGene appoints Astley-Sparke, Grossman, Heffernan to board; promotes three executives

enGene Therapeutics Inc.

Philip Astley-Sparke, William Grossman, Michael Heffernan appointed to Board effective July 8, 2025; Jasper Bos resigned.
Matthew Boyd promoted to Chief Regulatory Officer; Jill Buck to Chief Development Officer; Katherine Chan to Executive Director, Urology Clinical Lead.
New board members have experience in gene therapy, oncology, and product launches; company advancing detalimogene toward planned commercialization.
Board increased from seven to nine members after appointments; no disagreements cited for Bos resignation.
Independent director compensation plan applies; indemnification agreements entered.

item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.